

Research article

Open Access

The promoter polymorphism -232C/G of the *PCK1* gene is associated with type 2 diabetes in a UK-resident South Asian population

Simon D Rees*¹, Abigail C Britten¹, Srikanth Bellary^{1,2}, J Paul O'Hare³, Sudhesh Kumar³, Anthony H Barnett^{1,2} and M Ann Kelly¹

Address: ¹College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK, ²Heart of England NHS Foundation Trust, Birmingham, UK and ³Warwick Medical School, University of Warwick, Coventry, UK

Email: Simon D Rees* - s.d.rees@bham.ac.uk; Abigail C Britten - a.c.britten@bham.ac.uk; Srikanth Bellary - sribell@hotmail.com; J Paul O'Hare - J.P.O-Hare@warwick.ac.uk; Sudhesh Kumar - sudhesh.kumar@warwick.ac.uk; Anthony H Barnett - anthony.barnett@heartofengland.nhs.uk; M Ann Kelly - m.a.kelly@bham.ac.uk

* Corresponding author

Published: 2 September 2009

Received: 26 January 2009

BMC Medical Genetics 2009, 10:83 doi:10.1186/1471-2350-10-83

Accepted: 2 September 2009

This article is available from: <http://www.biomedcentral.com/1471-2350/10/83>

© 2009 Rees et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background: The *PCK1* gene, encoding cytosolic phosphoenolpyruvate carboxykinase (PEPCK-C), has previously been implicated as a candidate gene for type 2 diabetes (T2D) susceptibility. Rodent models demonstrate that over-expression of *Pck1* can result in T2D development and a single nucleotide polymorphism (SNP) in the promoter region of human *PCK1* (-232C/G) has exhibited significant association with the disease in several cohorts. Within the UK-resident South Asian population, T2D is 4 to 6 times more common than in indigenous white Caucasians. Despite this, few studies have reported on the genetic susceptibility to T2D in this ethnic group and none of these has investigated the possible effect of *PCK1* variants. We therefore aimed to investigate the association between common variants of the *PCK1* gene and T2D in a UK-resident South Asian population of Punjabi ancestry, originating predominantly from the Mirpur area of Azad Kashmir, Pakistan.

Methods: We used TaqMan assays to genotype five tagSNPs covering the *PCK1* gene, including the -232C/G variant, in 903 subjects with T2D and 471 normoglycaemic controls.

Results: Of the variants studied, only the minor allele (G) of the -232C/G SNP demonstrated a significant association with T2D, displaying an OR of 1.21 (95% CI: 1.03 - 1.42, $p = 0.019$).

Conclusion: This study is the first to investigate the association between variants of the *PCK1* gene and T2D in South Asians. Our results suggest that the -232C/G promoter polymorphism confers susceptibility to T2D in this ethnic group.

Trial Registration: UKADS Trial Registration: ISRCTN38297969

Background

Cytosolic phosphoenolpyruvate carboxykinase (PEPCK-C), encoded by the *PCK1* gene in humans, is an enzyme centrally involved in gluconeogenesis, glyceroneogenesis and cataplerosis. Normal expression of *PCK1* is under hormonal control, regulated at the transcriptional level by both activators, such as glucagon, and inhibitors, such as insulin. The metabolic functions of PEPCK-C advocate the *PCK1* gene as a strong candidate for conferring susceptibility to type 2 diabetes (T2D), a theory that is supported by the effects of gene modulation in mouse and rat models. These include over-expression of PEPCK-C resulting in insulin resistance and T2D [1].

Genetic studies have previously implicated the region of chromosome 20q in which *PCK1* lies in T2D susceptibility [2,3]. Cao *et al.* [4] reported on the discovery of a single nucleotide polymorphism (SNP) in the promoter region of *PCK1* (-232C/G) that was associated with T2D in Canadian Caucasian and Oji-Cree cohorts (odds ratio (OR) = 2.8, 95% CI 1.7 - 4.7, $p = 4 \times 10^{-5}$ and OR = 1.9, 95% CI 1.2 - 3.0, $p = 9 \times 10^{-3}$ respectively). In addition, luciferase reporter assays demonstrated that the -232G allele increased expression of *PCK1* compared to the -232C allele in multiple cell lines, with no down regulation by insulin. As with many genetic association studies investigating polygenic diseases, attempts to replicate the association between *PCK1* and T2D have produced mixed results. A haplotype of *PCK1* variants was shown to confer risk of developing the disease in a Korean population (OR not given, $p = 6 \times 10^{-3}$) [5], and a screen of 134 candidate susceptibility SNPs showed that the -232C/G SNP was a risk factor for T2D in a Finnish cohort (OR = 1.27, 95% CI 1.02 - 1.57, $p = 0.031$) [6]. A recent study reported that multiple *PCK1* variants are associated with T2D in a Chinese population [7]. The authors of this paper reported -232C as a risk allele, although its association with the disease fell short of statistical significance (OR = 1.24, 95% CI 1.00 - 1.55, $p = 0.057$). Studies investigating other populations, however, have found no evidence for an association between *PCK1* variants and T2D [8,9].

Within the UK, T2D is 4 to 6 times more common in the South Asian population compared to the indigenous white Caucasian population [10]. Over 10% of South Asian adults will develop the disease and yet only a small number of investigations have reported on the genetic susceptibility to T2D in this ethnic group. None of these studies has looked into the possible effects of the *PCK1* gene. We therefore aimed to investigate the association between common variants of the *PCK1* gene and T2D in a UK-resident South Asian population of Punjabi ancestry.

Methods

Type 2 diabetic subjects (N = 903) were recruited to the United Kingdom Asian Diabetes Study (UKADS), a multi-

ple risk factor intervention trial investigating the impact of a culturally-sensitive, enhanced diabetes care package on the risk of cardiovascular disease in South Asian type 2 diabetes patients living in Birmingham and Coventry, UK [11]. All subjects were of Punjabi ancestry, confirmed over three generations, and originated predominantly from the Mirpur area of Azad Kashmir, Pakistan. Ethnically-matched normoglycaemic control subjects (N = 471) were recruited from the same geographical areas through community screening. Normal glucose tolerance was defined as fasting plasma glucose <6 mmol/l and 2 hr plasma glucose <7.8 mmol/l on a 75 g OGTT. Where OGTT was not feasible, normal glucose tolerance was defined as random blood glucose <7 mmol/l. Venous blood was collected from each subject after obtaining informed consent and genomic DNA extracted using an adaptation of the Nucleon[®] protocol (Nucleon Biosciences, Coatbridge, UK). The study was approved by the Birmingham East, North and Solihull Research Ethics Committee.

SNP selection and genotyping

In addition to investigating the -232C/G promoter polymorphism (rs2071023), we also utilised Haploview 3.2 [12] to tag SNPs within the entire *PCK1* gene. To do this we used data from the CEPH (CEU) HapMap samples (Utah residents with ancestry from northern and western Europe)[13], as this population was the closest proxy for our South Asian population available on the HapMap at the time tag SNPs were chosen. Our criteria for tagging SNPs were $r^2 \geq 0.7$ and a minor allele frequency (MAF) ≥ 0.15 , using pairwise tagging only. This resulted in four extra SNPs (rs6070157, rs2070756, rs2179706 and rs1042531) for analysis. All SNPs were genotyped using TaqMan SNP Genotyping assays (Applied Biosystems, Warrington, UK) and fluorescence was measured using an ABI 7900 sequence detection system (Applied Biosystems).

Statistical analyses

Genotype frequencies for each SNP were checked for Hardy-Weinberg equilibrium using a chi square goodness-of-fit test. Pairwise linkage disequilibrium (LD) between SNPs was estimated using Haploview version 3.2. Variants were tested for association with type 2 diabetes using logistic regression, assuming an additive genetic model. Possible confounding variables (BMI, gender, family history of T2D) were initially included in the logistic regression as covariates. Haplotype analyses were performed using Haploview version 3.2. Association between genotypes and continuous variables was tested using analysis of variance (ANOVA). The significance of the relationship between OR and minimum age threshold was determined using linear regression. All of the above statistical analyses were implemented in SPSS version 13.0 (SPSS Inc, Chicago IL). Power calculations were performed using Genetic Power Calculator [14].

Results

The clinical characteristics of the subjects in our study are shown in Table 1. Age of diagnosis, HDL cholesterol and HbA_{1c} data were available for subjects with diabetes only, whereas BMI, waist circumference and blood pressure measurements were available for both the diabetic group and a maximum of 279 subjects from the control group. Genotypes of the studied *PCK1* SNPs were not significantly associated with any clinical, biochemical or morphological characteristic measured (Table 2).

LD patterns (Figure 1) and allele frequencies for all variants were generally similar to those seen in the CEPH (CEU) HapMap samples (CEU allele frequencies: rs2071023 (G) - 0.52, rs6070157 (T) - 0.21, rs2070756 (T) - 0.25, rs2179706 (T) - 0.52, rs1042531 (G) - 0.31). Genotyping success rate was $\geq 97.5\%$ for all SNPs studied. Approximately 15% of all individuals were re-genotyped for the estimation of error rate, which was $<1\%$ for all variants. All SNPs conformed to Hardy-Weinberg equilibrium with the exception of rs6070157 ($p = 0.01$). As the error rate for this SNP was zero and it displayed no significant association with any variable measured, no further action was taken to investigate this anomaly.

Of the variants studied, only the minor allele of rs2071023 displayed a significant association with T2D, with an OR of 1.21 (95% CI 1.03 - 1.42, $p = 0.019$; Table 3). A number of clinical and morphological characteristics (gender, BMI, family history of T2D) were included as

covariates in our initial analyses, but had no qualitative effect on the observed association and so were excluded from the final model. As statistical power was low for all variants ($\leq 72\%$ power to reject a false negative for all variants), we cannot categorically state that the other SNPs studied confer no susceptibility to T2D. We have previously confirmed that variants of *TCF7L2* confer susceptibility to T2D in this population [15]. Genotype of the *TCF7L2* SNP rs7903146 was therefore included in the logistic regression model as a covariate, but had no effect on the results and so was excluded from the final model.

Only one haplotype, comprising the rs2071023 G allele and the rs6070157 C allele, was significantly associated with T2D (Haplotype 1; OR = 1.20, $p = 0.024$; Table 4). This was the only haplotype to contain the rs2071023 G allele and the effect on disease risk was similar to that of rs2071023 alone, suggesting that the haplotype association was due solely to the rs2071023 SNP.

Including young control subjects within a case-control analysis can artificially reduce effect size and statistical significance, as it can increase the chance of including subjects who will develop T2D later in life. As we have done previously with *TCF7L2* [15], we re-analyzed our data using subsets of the control group defined by different minimum age cut-offs. For SNP rs2071023 there was a significant relationship between control-group minimum age cut-off and both OR ($r^2 = 0.912$, $p = 3.86 \times 10^{-7}$) and statistical significance of the logistic regression test ($r^2 =$

Table 1: Clinical characteristics of subjects studied

| | Diabetic subjects | | Control subjects | |
|--|-------------------|------------------|------------------|------------------|
| | Male | Female | Male | Female |
| n | 494 | 409 | 230 | 241 |
| Age at study (years) | 57.1 \pm 11.9 | 56.7 \pm 12.3 | 57.1 \pm 11.8 | 53.0 \pm 11.6 |
| Age at diagnosis (years) | 49.8 \pm 11.7 | 49.3 \pm 12.3 | NA ^a | NA ^a |
| BMI (kg/m ²) | 27.4 \pm 4.1 | 30.0 \pm 4.9 | 27.1 \pm 4.1 | 28.9 \pm 5.3 |
| Waist circumference (cm) ^c | 100.9 \pm 10.1 | 104.2 \pm 11.0 | 100.5 \pm 11.2 | 99.0 \pm 13.8 |
| Systolic blood pressure (mm Hg) ^c | 141.4 \pm 19.3 | 138.9 \pm 22.5 | 139.5 \pm 19.6 | 131.1 \pm 20.2 |
| Diastolic blood pressure (mm Hg) | 84.5 \pm 12.6 | 84.1 \pm 12.0 | 86.0 \pm 11.6 | 82.9 \pm 12.1 |
| HDL cholesterol (mmol/l) | 1.3 \pm 0.6 | 1.3 \pm 0.4 | ND ^b | ND ^b |
| HbA _{1c} (%) | 8.3 \pm 2.0 | 8.3 \pm 1.7 | ND ^b | ND ^b |

Data are expressed as means \pm SD. ^aNA = not applicable. ^bND = not determined. ^c = significant difference between diabetic and control groups (t-test; $p < 0.01$).

Table 2: Clinical characteristics of subjects studied

| rs2071023 | Diabetic subjects | | | Control subjects | | |
|----------------------------------|-------------------|--------------|--------------|------------------|--------------|--------------|
| | CC | CG | GG | CC | CG | GG |
| BMI (kg/m ²) | 28.8 ± 4.6 | 28.4 ± 4.7 | 28.9 ± 4.7 | 28.5 ± 5.2 | 27.7 ± 4.8 | 28.3 ± 4.1 |
| Waist circumference (cm) | 102.8 ± 10.5 | 102.1 ± 11.0 | 103.0 ± 10.0 | 100.1 ± 13.4 | 98.8 ± 11.5 | 101.5 ± 13.7 |
| Systolic blood pressure (mm Hg) | 140.6 ± 20.6 | 139.7 ± 20.1 | 141.1 ± 22.7 | 134.4 ± 19.3 | 135.2 ± 20.5 | 136.3 ± 22.2 |
| Diastolic blood pressure (mm Hg) | 84.0 ± 11.5 | 84.2 ± 13.2 | 85.2 ± 11.8 | 84.8 ± 11.2 | 84.2 ± 12.2 | 84.1 ± 12.7 |
| HDL cholesterol (mmol/l) | 1.3 ± 0.5 | 1.3 ± 0.5 | 1.3 ± 0.5 | ND | ND | ND |
| HbA _{1c} (%) | 8.3 ± 1.8 | 8.2 ± 1.8 | 8.4 ± 2.1 | ND | ND | ND |
| rs6070157 | CC | CT | TT | CC | CT | TT |
| BMI (kg/m ²) | 28.6 ± 4.7 | 28.6 ± 4.8 | 28.0 ± 3.4 | 28.0 ± 4.7 | 28.1 ± 5.0 | 28.7 ± 5.3 |
| Waist circumference (cm) | 102.5 ± 10.3 | 102.4 ± 11.0 | 102.0 ± 13.4 | 99.5 ± 13.0 | 99.0 ± 12.1 | 103.8 ± 10.4 |
| Systolic blood pressure (mm Hg) | 140.1 ± 20.9 | 140.5 ± 20.5 | 139.3 ± 19.9 | 133.9 ± 20.5 | 136.6 ± 20.1 | 139.6 ± 20.3 |
| Diastolic blood pressure (mm Hg) | 84.3 ± 11.7 | 84.6 ± 14.4 | 83.9 ± 7.9 | 83.6 ± 12.0 | 85.5 ± 12.3 | 86.4 ± 9.9 |
| HDL cholesterol (mmol/l) | 1.3 ± 0.5 | 1.3 ± 0.5 | 1.2 ± 0.3 | ND | ND | ND |
| HbA _{1c} (%) | 8.4 ± 2.0 | 8.2 ± 1.7 | 8.0 ± 1.6 | ND | ND | ND |
| rs2070756 | CC | CT | TT | CC | CT | TT |
| BMI (kg/m ²) | 28.5 ± 4.5 | 28.7 ± 4.8 | 28.3 ± 4.5 | 28.0 ± 4.9 | 27.9 ± 4.8 | 29.1 ± 5.0 |
| Waist circumference (cm) | 102.2 ± 10.7 | 102.8 ± 10.6 | 102.3 ± 10.2 | 99.4 ± 12.3 | 99.3 ± 12.9 | 102.7 ± 13.8 |
| Systolic blood pressure (mm Hg) | 139.6 ± 20.5 | 141.8 ± 21.6 | 138.7 ± 19.1 | 134.7 ± 20.3 | 136.9 ± 20.7 | 132.8 ± 19.5 |
| Diastolic blood pressure (mm Hg) | 84.7 ± 13.0 | 84.3 ± 12.0 | 83.5 ± 10.4 | 84.8 ± 11.5 | 84.0 ± 12.0 | 84.1 ± 14.2 |
| HDL cholesterol (mmol/l) | 1.3 ± 0.5 | 1.3 ± 0.5 | 1.3 ± 0.4 | ND | ND | ND |
| HbA _{1c} (%) | 8.2 ± 1.9 | 8.3 ± 1.8 | 8.5 ± 2.1 | ND | ND | ND |
| rs2179706 | CC | CT | TT | CC | CT | TT |
| BMI (kg/m ²) | 28.7 ± 4.9 | 28.5 ± 4.6 | 28.5 ± 4.4 | 28.5 ± 4.6 | 27.8 ± 4.8 | 27.8 ± 5.1 |
| Waist circumference (cm) | 103.0 ± 10.5 | 102.0 ± 10.7 | 102.4 ± 10.8 | 102.6 ± 13.8 | 98.1 ± 11.7 | 98.3 ± 12.1 |
| Systolic blood pressure (mm Hg) | 141.2 ± 20.8 | 140.2 ± 21.7 | 139.2 ± 18.7 | 134.4 ± 21.0 | 135.0 ± 19.6 | 137.0 ± 21.0 |
| Diastolic blood pressure (mm Hg) | 84.8 ± 11.1 | 83.9 ± 13.9 | 85.3 ± 10.5 | 83.5 ± 12.2 | 85.1 ± 12.0 | 84.7 ± 11.0 |
| HDL cholesterol (mmol/l) | 1.3 ± 0.5 | 1.3 ± 0.5 | 1.2 ± 0.3 | ND | ND | ND |
| HbA _{1c} (%) | 8.4 ± 2.0 | 8.3 ± 1.8 | 8.0 ± 1.7 | ND | ND | ND |
| rs1042531 | TT | GT | GG | TT | GT | GG |
| BMI (kg/m ²) | 28.4 ± 4.4 | 28.9 ± 4.8 | 28.4 ± 5.2 | 28.2 ± 5.1 | 27.5 ± 4.6 | 29.1 ± 4.0 |
| Waist circumference (cm) | 102.2 ± 10.2 | 103.1 ± 11.0 | 101.3 ± 11.2 | 99.7 ± 13.0 | 99.1 ± 11.3 | 101.5 ± 17.1 |
| Systolic blood pressure (mm Hg) | 139.2 ± 20.3 | 140.2 ± 20.6 | 144.5 ± 22.8 | 135.9 ± 20.0 | 136.1 ± 20.2 | 128.3 ± 22.2 |
| Diastolic blood pressure (mm Hg) | 83.6 ± 11.0 | 84.8 ± 14.1 | 85.8 ± 10.4 | 85.4 ± 11.6 | 84.0 ± 12.2 | 82.4 ± 12.5 |
| HDL cholesterol (mmol/l) | 1.3 ± 0.4 | 1.3 ± 0.5 | 1.3 ± 0.6 | ND | ND | ND |
| HbA _{1c} (%) | 8.2 ± 1.8 | 8.3 ± 1.8 | 8.5 ± 2.4 | ND | ND | ND |

Genotypes of the studied *PCK1* variants were not significantly associated with any measured clinical characteristic (ANOVA; $p > 0.05$ for all tests). Data are expressed as means ± SD. ND = not determined.

0.838, $p = 1.12 \times 10^{-5}$), up until maximum statistical significance (minimum p -value) was reached at an age cut-off of 47 years. At this age cut-off the effect size of the association had greatly increased (OR = 1.31, 95% CI 1.10 - 1.56, $p = 2 \times 10^{-3}$), remaining significant even after correcting for multiple testing (Bonferroni correction for testing 5 SNPs, $p = 0.015$). After this age cut-off both relationships began to deteriorate as the number of individuals within the control group was further reduced. It is interest-

ing to note that when an age cut-off of 47 years was applied to the control group, statistical power actually increased to 90% due to the increase in OR, despite a drop in subject numbers.

Discussion

As previously reported in a number of studies[4,6] our results suggest that the -232C/G SNP (rs2071023) located



Figure 1
Pairwise linkage disequilibrium (LD) in CEPH (CEU) HapMap samples and the Pakistani study population. LD expressed as D' and r^2 for the CEPH (CEU) HapMap samples and the Pakistani study population. Blank squares equate to a D' value of 1.

in the promoter region of the PEPCK-C-encoding *PCK1* gene is associated with T2D.

It has been suggested that T2D could be caused by either excessive PEPCK-C production in the liver or reduced levels of PEPCK-C in adipose tissue [16]. In addition, from expression analysis of luciferase reporter constructs in multiple cell lines, Cao *et al.* [4] demonstrated that the -232G risk allele resulted in increased basal gene expression when compared to the -232C allele. It is possible, therefore, that the -232C/G polymorphism may confer increased risk of T2D development by increasing *PCK1* expression in the liver. This would result in an upregulation of gluconeogenesis and increased blood glucose levels. Unfortunately we were not able to investigate the

relationship between *PCK1* genotype and blood glucose levels in this study, as fasting blood glucose data were only available for a small subset of our control subjects. Interestingly, a recent study has shown that liver-specific silencing of *Pck1* can improve glycaemic control and insulin sensitivity in a T2D mouse model [17], supporting the role of PEPCK-C in T2D pathology and providing a potential therapeutic target for treatment of the disease.

Although the use of our entire cohort resulted in an OR of 1.21, the removal of young control subjects should have increased the validity of the control group. The OR of 1.31 resulting from our reduced dataset, similar to that seen in a Finnish cohort (OR = 1.27) [6], may therefore be a more representative estimate of the true effect size of this SNP,

Table 3: Association of PCK1 variants with type 2 diabetes among UK-resident South Asians

| SNP | Gene Region | Allele | Diabetic subjects F ^a | Control subjects F ^a | Genotype | Diabetic subjects n (%) ^b | Control subjects n (%) ^b | Allelic OR ^c (95% CI) |
|-----------|-------------|--------|----------------------------------|---------------------------------|----------|--------------------------------------|-------------------------------------|---|
| rs2071023 | Promoter | C | 0.53 | 0.57 | CC | 243 (0.27) | 158 (0.34) | 1.21 (1.03 - 1.42) <i>p</i> = 0.019 |
| | | | | | CG | 447 (0.51) | 225 (0.48) | |
| | | G | 0.47 | 0.43 | GG | 195 (0.22) | 88 (0.19) | |
| rs6070157 | Exon 3 | C | 0.81 | 0.79 | CC | 597 (0.67) | 305 (0.65) | 0.90 (0.74 - 1.08) <i>p</i> = 0.257 |
| | | | | | CT | 258 (0.29) | 135 (0.29) | |
| | | T | 0.19 | 0.21 | TT | 38 (0.04) | 29 (0.06) | |
| rs2070756 | Exon 7 | C | 0.72 | 0.71 | CC | 456 (0.52) | 246 (0.53) | 1.00 (0.84 - 1.18) <i>p</i> = 0.965 |
| | | | | | CT | 354 (0.40) | 171 (0.37) | |
| | | T | 0.28 | 0.29 | TT | 75 (0.08) | 47 (0.10) | |
| rs2179706 | Intron 8 | C | 0.58 | 0.56 | CC | 298 (0.34) | 156 (0.34) | 0.92 (0.79 - 1.08) <i>p</i> = 0.323 |
| | | | | | CT | 424 (0.48) | 206 (0.45) | |
| | | T | 0.42 | 0.44 | TT | 156 (0.18) | 100 (0.22) | |
| rs1042531 | 3'UTR | T | 0.66 | 0.68 | TT | 391 (0.44) | 206 (0.45) | 1.06 (0.89 - 1.25) <i>p</i> = 0.528 |
| | | | | | GT | 384 (0.44) | 212 (0.46) | |
| | | G | 0.34 | 0.32 | GG | 104 (0.12) | 44 (0.10) | |

^aF = Allele frequency. ^bGenotype frequency expressed as number of individuals, n - values in parentheses indicate percentage. ^cOR = odds ratio, 95% CI = 95% confidence interval. Allelic OR refers to the risk associated with a single copy of the risk allele. All values were calculated using the full dataset, the minimum age of control subjects being 35 years.

one that is not inconsiderable compared to recently discovered T2D susceptibility variants.

There are a number of limiting factors to be considered when interpreting our results. Firstly, our cohort is limited in size. Secondly, there is the possibility of cryptic relatedness within our cohort as the study subjects were recruited from a relatively small migrant population. In addition to this consanguinity is relatively common in the Mirpuri population. These limitations increase the risk of our result being a false positive. Unfortunately we cannot control for relatedness in our analyses as we do not have the necessary data. The impact of cryptic relatedness on association studies, however, increases with sample size [18], so it may be that our relatively small cohort is to some

degree protected from this effect. Furthermore, we have no reason to believe that the degree of relatedness would differ significantly between the diabetic and control groups and so the effect of any cryptic relatedness may be negated.

Conclusion

This study is the first to investigate the association between variants of the PCK1 gene and T2D in South Asians. In agreement with studies in other ethnic groups [4,6], our analyses suggest that the -232C/G promoter SNP (rs2071023) confers susceptibility to T2D. Due to the limitations discussed within this manuscript, however, we cannot exclude the possibility that our findings are a false positive result. We strongly advocate that replication of

Table 4: Association of PCK1 haplotypes with type 2 diabetes among UK-resident South Asians

| LD Block | Haplotype | SNP1 | SNP2 | SNP3 | SNP4 | Diabetic subjects F ^a | Control subjects F ^a | Odds ratio (OR) | <i>p</i> |
|----------|-------------|------|------|------|------|----------------------------------|---------------------------------|-----------------|----------|
| 1 | Haplotype 1 | G | C | - | - | 0.472 | 0.427 | 1.20 | 0.024 |
| | Haplotype 2 | C | C | - | - | 0.341 | 0.369 | 0.89 | 0.150 |
| | Haplotype 3 | C | T | - | - | 0.185 | 0.204 | 0.89 | 0.239 |
| 2 | Haplotype 4 | - | - | C | T | 0.405 | 0.417 | 0.95 | 0.538 |
| | Haplotype 5 | - | - | C | C | 0.311 | 0.297 | 1.06 | 0.475 |
| | Haplotype 6 | - | - | T | C | 0.271 | 0.264 | 1.03 | 0.710 |
| | Haplotype 7 | - | - | T | T | 0.014 | 0.021 | 0.63 | 0.130 |

^aF = Haplotype frequency. All values were calculated using the full dataset, the minimum age of control subjects being 35 years. SNP1 = rs2071023, SNP2 = rs6070157, SNP3 = rs2070756, SNP4 = rs2179706.

this association in larger independent South Asian cohorts is needed to confirm the -232C/G polymorphism of *PCK1* as a true T2D susceptibility variant in this ethnic group.

Competing interests

None of the authors declare any competing interests. The United Kingdom Asian Diabetes Study received financial support from all companies mentioned in the Acknowledgements.

Authors' contributions

SDR participated in the genotyping of samples, performed statistical analyses and drafted the manuscript. ACB performed DNA extraction and genotyping. MAK participated in the drafting of the manuscript. All authors contributed to the intellectual content of the paper, and have read and approved the final manuscript.

Acknowledgements

The authors would like to thank all the patients and control subjects for agreeing to participate in this study. We are grateful to Dr. Anthony Dixon, Shanaz Mughal, Kam Johal and Tahera Mehrali for recruiting the study subjects and coordinating data collection, and to Karen Jones for help with DNA extraction. The United Kingdom Asian Diabetes Study was supported by Pfizer, Sanofi-Aventis, Servier Laboratories UK, Merck Sharp & Dohme/Schering-Plough, Takeda UK, Roche, Merck Pharma, Daiichi-Sankyo UK, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Bristol-Myers Squibb, Solvay Health Care and Assurance Medical Society UK. Funding for genetic analyses was provided by Eli Lilly.

References

- Valera A, Pujol A, Pelegrin M, Bosch F: **Transgenic mice overexpressing phosphoenolpyruvate carboxykinase develop non-insulin-dependent diabetes mellitus.** *Proc Natl Acad Sci USA* 1994, **91**:9151-9154.
- Hani EH, Zouali H, Philippi A, Beaudoin JC, Vionnet N, Passa P, Demenais F, Froguel P: **Indication for genetic linkage of the phosphoenolpyruvate carboxykinase (PCK1) gene region on chromosome 20q to non-insulin-dependent diabetes mellitus.** *Diabetes Metab* 1996, **22**:451-454.
- Zouali H, Hani EH, Philippi A, Vionnet N, Beckmann JS, Demenais F, Froguel P: **A susceptibility locus for early-onset non-insulin dependent (type 2) diabetes mellitus maps to chromosome 20q, proximal to the phosphoenolpyruvate carboxykinase gene.** *Hum Mol Genet* 1997, **6**:1401-1408.
- Cao H, van der Veer E, Ban MR, Hanley AJ, Zinman B, Harris SB, Young TK, Pickering JG, Hegele RA: **Promoter polymorphism in PCK1 (phosphoenolpyruvate carboxykinase gene) associated with type 2 diabetes mellitus.** *J Clin Endocrinol Metab* 2004, **89**:898-903.
- Shin HD, Park BL, Kim LH, Cheong HS, Kim JH, Cho YM, Lee HK, Park KS: **Association of a polymorphism in the gene encoding phosphoenolpyruvate carboxykinase 1 with high-density lipoprotein and triglyceride levels.** *Diabetologia* 2005, **48**:2025-2032.
- Willer CJ, Bonnycastle LL, Conneely KN, Duren VL, Jackson AU, Scott LJ, Narisu N, Chines PS, Skol A, Stringham HM, et al.: **Screening of 134 single nucleotide polymorphisms (SNPs) previously associated with type 2 diabetes replicates association with 12 SNPs in nine genes.** *Diabetes* 2007, **56**:256-264.
- Dong Y, Zhang H, Wang X, Feng Q, Chen X, Su Q: **A Leu184Val polymorphism in PCK1 gene is associated with type 2 diabetes in Eastern Chinese population with BMI<23 kg/m².** *Diabetes Res Clin Pract* 2009, **83**:227-232.
- Gouni-Berthold I, Giannakidou E, Faust M, Berthold HK, Krone W: **Association of the promoter polymorphism -232C/G of the phosphoenolpyruvate carboxykinase gene (PCK1) with Type 2 diabetes mellitus.** *Diabet Med* 2006, **23**:419-425.
- Wegner L, Andersen G, Albrechtsen A, Sparso T, Glumer C, Borch-Johnsen K, Jorgensen T, Hansen T, Pedersen O: **Large-scale study of the -232C > G polymorphism of PCK1 in Type 2 diabetes.** *Diabet Med* 2006, **23**:1140-1144.
- Barnett AH, Dixon AN, Bellary S, Hanif MW, O'Hare JP, Raymond NT, Kumar S: **Type 2 diabetes and cardiovascular risk in the UK south Asian community.** *Diabetologia* 2006, **49**:2234-2246.
- Bellary S, O'Hare JP, Raymond NT, Gumber A, Mughal S, Szczepura A, Kumar S, Barnett AH: **Enhanced diabetes care to patients of south Asian ethnic origin (the United Kingdom Asian Diabetes Study): a cluster randomised controlled trial.** *Lancet* 2008, **371**:1769-1776.
- Barrett JC, Fry B, Maller J, Daly MJ: **Haploview: analysis and visualization of LD and haplotype maps.** *Bioinformatics* 2005, **21**:263-265.
- The International HapMap Consortium: **The International HapMap Project.** *Nature* 2003, **426**:789-796.
- Purcell S, Cherny SS, Sham PC: **Genetic Power Calculator: design of linkage and association genetic mapping studies of complex traits.** *Bioinformatics* 2003, **19**:149-150.
- Rees SD, Bellary S, Britten AC, O'Hare JP, Kumar S, Barnett AH, Kelly MA: **Common variants of the TCF7L2 gene are associated with increased risk of type 2 diabetes mellitus in a UK-resident South Asian population.** *BMC Med Genet* 2008, **9**:8.
- Beale EG, Hammer RE, Antoine B, Forest C: **Disregulated glyceroneogenesis: PCK1 as a candidate diabetes and obesity gene.** *Trends Endocrinol Metab* 2004, **15**:129-135.
- Gomez-Valades AG, Mendez-Lucas A, Vidal-Alabro A, Blasco FX, Chillón M, Bartrons R, Bermudez J, Perales JC: **Pck1 gene silencing in the liver improves glycemia control, insulin sensitivity, and dyslipidemia in db/db mice.** *Diabetes* 2008, **57**:2199-2210.
- Voight BF, Pritchard JK: **Confounding from cryptic relatedness in case-control association studies.** *PLoS Genet* 2005, **1**:e32.

Pre-publication history

The pre-publication history for this paper can be accessed here:

<http://www.biomedcentral.com/1471-2350/10/83/prepub>

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

